Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...
Hosted on MSN24y
How Peptides for Weight Loss Work: What You Should Know
Medically reviewed by Anju Goel, MD Many peptide medications like glucagon-like peptide-1 (GLP-1) receptor agonists were ...
GlobalData on MSN14d
Palatin concludes Phase II trial of combination therapy for obesity
Palatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 receptor (MC4R) bremelanotide with tirzepatide, a glucagon-like peptide-1 ...
Business Insider21d
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained widespread ...
Nature2mon
Peptide gut hormones influence weight loss after gastric bypass
Gut hormones that influence satiety, such as peptide YY (PYY ... the role of gut hormones in appetite change after Roux-en-Y gastric bypass. Le Roux et al. measured fasting and postprandial ...